HuGE Literature Finder
Records 1-17
|
SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Aug . Boysen Gunther, Nava Rodrigues Daniel, Rescigno Pasquale, Seed George, Dolling David I, Riisnaes Ruth, Crespo Mateus, Zafeiriou Zafeiris, Sumanasuriya Semini, Bianchini Diletta, Hunt Joanne, Moloney Deirdre, Perez-Lopez Raquel, Tunariu Nina, Miranda Susana, Figueiredo Ines, Ferreira Ana, Christova Rossitza, Gil Veronica, Aziz Sara, Bertan Claudia, de Oliveira Flavia M, Atkin Mark, Clarke Matthew, Goodall Jane, Sharp Adam, MacDonald Theresa Y, Rubin Mark A, Yuan Wei, Barbieri Christopher E, Carreira Suzanne, Mateo Joaquin, de Bono Johann |
|
The genetic landscape of ganglioglioma.
Acta neuropathologica communications 2018 Jun 6 (1): 47. Pekmezci Melike, Villanueva-Meyer Javier E, Goode Benjamin, Van Ziffle Jessica, Onodera Courtney, Grenert James P, Bastian Boris C, Chamyan Gabriel, Maher Ossama M, Khatib Ziad, Kleinschmidt-DeMasters Bette K, Samuel David, Mueller Sabine, Banerjee Anuradha, Clarke Jennifer L, Cooney Tabitha, Torkildson Joseph, Gupta Nalin, Theodosopoulos Philip, Chang Edward F, Berger Mitchel, Bollen Andrew W, Perry Arie, Tihan Tarik, Solomon David |
|
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Oncotarget 2017 Nov 8 (55): 93464-93475. Gleeson Ferga C, Voss Jesse S, Kipp Benjamin R, Kerr Sarah E, Van Arnam John S, Mills John R, Marcou Cherisse A, Schneider Amber R, Tu Zheng Jin, Henry Michael R, Levy Michael |
|
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Oncotarget 2017 Jun . Gleeson Ferga C, Voss Jesse S, Kipp Benjamin R, Kerr Sarah E, Van Arnam John S, Mills John R, Marcou Cherisse A, Schneider Amber R, Jin Tu Zheng, Henry Michael R, Levy Michael |
|
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Gynecologic oncology 2017 Jan . Spreafico A, Oza A M, Clarke B A, Mackay H J, Shaw P, Butler M, Dhani N C, Lheureux S, Wilson M K, Welch S, Zhang T, Yu C, Stockley T, Siu L L, Kamel-Reid S, Bedard P |
|
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
BMC cancer 2016 Nov 16 (1): 864. Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshia |
|
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Cancer 2016 Sep . Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R, Aghajanian Carol |
|
A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.
EBioMedicine 2015 Dec 2 (12): 1957-64. Petrovics Gyorgy, Li Hua, Stümpel Tanja, Tan Shyh-Han, Young Denise, Katta Shilpa, Li Qiyuan, Ying Kai, Klocke Bernward, Ravindranath Lakshmi, Kohaar Indu, Chen Yongmei, Ribli Dezs?, Grote Korbinian, Zou Hua, Cheng Joseph, Dalgard Clifton L, Zhang Shimin, Csabai István, Kagan Jacob, Takeda David, Loda Massimo, Srivastava Sudhir, Scherf Matthias, Seifert Martin, Gaiser Timo, McLeod David G, Szallasi Zoltan, Ebner Reinhard, Werner Thomas, Sesterhenn Isabell A, Freedman Matthew, Dobi Albert, Srivastava Sh |
|
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
International journal of clinical and experimental pathology 2015 8 (10): 13314-22. Lin Lin, Zhang Zhaoxu, Zhang Wen, Wang Lin, Wang Jinw |
|
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013 Dec 22 (12): 2333-44. Leinonen Katri A, Saramäki Outi R, Furusato Bungo, Kimura Takahiro, Takahashi Hiroyuki, Egawa Shin, Suzuki Hiroyoshi, Keiger Kerri, Ho Hahm Sung, Isaacs William B, Tolonen Teemu T, Stenman Ulf-Håkan, Tammela Teuvo L J, Nykter Matti, Bova G Steven, Visakorpi Tap |
|
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/?-catenin and P53 pathway activation.
Gynecologic oncology 2012 Sep 126 (3): 466-73. Nout Remi A, Bosse Tjalling, Creutzberg Carien L, Jürgenliemk-Schulz Ina M, Jobsen Jan J, Lutgens Ludy C H W, van der Steen-Banasik Elzbieta M, van Eijk Ronald, Ter Haar Natalja T, Smit Vincent T H B |
|
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Asian Pacific journal of cancer prevention : APJCP 2012 13 (5): 2157-62. Xu Jia-Li, Wang Zhen-Wu, Hu Ling-Min, Yin Zhi-Qiang, Huang Ming-De, Hu Zhi-Bin, Shen Hong-Bing, Shu Yong-Qi |
|
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecologic oncology 2011 Jun 121 (3): 455-61. Usha Lydia, Sill Michael W, Darcy Kathleen M, Benbrook Doris M, Hurteau Jean A, Michelin David P, Mannel Robert S, Hanjani Parviz, De Geest Koen, Godwin Andrew |
|
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): 3530. Oliner K, Peeters M, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem J, Andre T, Wiezorek J S, Patterson S |
|
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
BJU international 2011 Feb 107 (3): 477-85. Bismar Tarek A, Yoshimoto Maisa, Vollmer Robin T, Duan Qiuli, Firszt Matthew, Corcos Jacques, Squire Jeremy |
|
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2011 Jan 71 (1): 82-8. Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xife |
|
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
BMC cancer 2011 11 (1): 248. Wang Leiping, Zhang Qunling, Zhang Jian, Sun Si, Guo Haiyi, Jia Zhen, Wang Biyun, Shao Zhimin, Wang Zhonghua, Hu Xich |
- Page last reviewed:Oct 1, 2020
- Page last updated:Nov 27, 2020
- Content source: